BRCA related breast cancer is a different entity because of the poor prognosis it carries. Recently new targets in these patients have resulted in new avenues.
PARP inhibitors — For patients with germline BRCA mutations and HER2-negative breast cancer, the oral inhibitor of polyadenosine diphosphate-ribose polymerase(PARP) Olaparib has shown satisfactory efficacy. In the OlympiAD trial, among 121 patients with metastatic triple-negative disease, all of whom had received an anthracycline and a taxane in either the adjuvant or metastatic setting, those randomly assigned to olaparib experienced an improved progression-free survival relative to those receiving chemotherapy (hazard ratio [HR] for progression or death 0.43, 95% CI 0.29-0.63).The study also included those with hormone receptor-positive, HER2-negative disease, was also positive, but the improvements noted with olaparib were…
